Medicare Part D coverage · 2 · RxCUI 2693791
2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss]
Per the CMS 2026 Part D formulary file, 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] is covered by 945 Medicare Part D plans (18.7% of enrollable products), averaging Tier 4.3, with prior authorization required on 93.8% of covering formularies.
- 18.7%
- Plan coverage
- 945
- Plans covering
- T4.3
- Avg tier
- 93.8%
- Prior auth required
What the CMS Formulary Data Shows for 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss]
Per the CMS 2026 Part D formulary file, 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] (RxNorm concept RXCUI 2693791, generic name 2) appears on 16 distinct formulary files spanning 945 Medicare Part D plan offerings - 18.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.3.
Real-world access to 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] depends on utilization management as much as tier placement: 93.8% of covering formularies require prior authorization. 0% require step therapy. 50% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] today.
Coverage Details
- Formularies covering
- 16
- Plans covering
- 945
- Coverage rate
- 18.7%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 93.8% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 50% of formularies
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T5 | Yes | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T5 | Yes | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss]
98 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| NaviCare (HMO D-SNP) | Fallon Community Health Plan | T1 | Yes | $0 | MA |
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | Yes | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | Yes | $0 | MA |
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T5 | Yes | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T5 | Yes | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T5 | Yes | $0 | VA |
| AARP Medicare Advantage from UHC AL-0001 (HMO-POS) | Unitedhealthcare OF THE Midlands, Inc. | T5 | Yes | $0 | AL |
Show the next 30 plans
Showing top 50 of 98 plans.
Frequently Asked Questions
Is 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] covered by Medicare Part D?
Yes, 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] is covered by 945 Medicare Part D plans (18.7% of all Part D formularies).
What tier is 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] on Medicare Part D plans?
2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] averages Tier 4.3 across Part D plans, ranging from Tier 1 to Tier 5.
Does 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss] require prior authorization?
93.8% of Part D formularies require prior authorization for 2 ML lebrikizumab-lbkz 125 MG/ML Prefilled Syringe [Ebglyss]. Step therapy: 0%. Quantity limits: 50%.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- {4 (selinexor 80 MG Oral Tablet [Xpovio]) } Pack [Xpovio 80 MG Once Weekly Carton-80 MG Tablet] T4.3
- 3.5 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega] T4.3
- 5 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega] T4.3
- ceftaroline fosamil 600 MG Injection T4.3
- 0.5 ML ustekinumab 90 MG/ML Prefilled Syringe T4.3
- 1 ML ustekinumab 90 MG/ML Prefilled Syringe T4.3
Similar prior-authorization rate
- degarelix 80 MG Injection [Firmagon] 93.8% PA
- 1 ML glatiramer acetate 20 MG/ML Prefilled Syringe [Copaxone] 93.8% PA
- tesamorelin 2 MG Injection [Egrifta] 93.8% PA
- deferasirox 90 MG Oral Tablet 93.7% PA
- Pediatric 1.5 ML leuprolide acetate 30 MG/ML Prefilled Syringe [Lupron] 93.7% PA
- lidocaine 0.018 MG/MG Medicated Patch [ZTlido] 93.9% PA